Organization
Cleveland Clinic Lerner College of Medicine
32 abstracts
Abstract
Evaluating the diagnostic performance of 18F-fluciclovine for detection of recurrent brain metastases after radiation therapy: Results from a prospective phase 2 trial.Org: Department of Neurosurgery, Prince of Wales Hospital, Department of Radiation Oncology, Baptist Health South Florida, Perelman School of Medicine, Department of Radiology,
Abstract
Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up.Org: Cleveland Clinic Lerner College of Medicine, University of California San Diego, Yale Cancer Center, University of California, San Francisco Medical Center, Stanford University School of Medicine, Division of Oncology,
Abstract
Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma.Org: Dana-Farber Cancer Institute, UPMC Hillman Cancer Center, Cleveland Clinic Lerner College of Medicine, Princess Margaret Cancer Centre, Moffitt Cancer Center,
Abstract
Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance).Org: Alliance Statistics and Data Management Center, Alliance Protocol Operations Office, Illinois CancerCare, Mayo Clinic, Trinity Health Saint Joseph Mercy Hospital,
Abstract
Polygenic risk score calibration and association with breast cancer in diverse ancestries.Org: Myriad Genetics, Inc., Vanderbilt University Medical Center, Abramson Cancer Center, University of Pennsylvania, Providence Health/St John Cancer Institute, Memorial Sloan Kettering Cancer Center,
Abstract
Metabolomic differences in young-onset versus average-onset colorectal adenocarcinoma.Org: Cleveland Clinic Lerner College of Medicine, Taussig Cancer Institute, Cleveland Clinic Lerner Research Institute,
Abstract
Phase 1/2 study of the TGF-β-trap-enhanced oncolytic adenovirus, AdAPT-001, plus an immune checkpoint inhibitor for patients with immune refractory cancers.Org: EpicentRx, Clinical Trials Innovations, Cleveland Clinic Lerner College of Medicine,
Abstract
Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).Org: Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, Université Paris-Sud, Université Paris-Saclay, Netherlands Cancer Institute,
Abstract
HB-200 arenavirus-based immunotherapy plus pembrolizumab as first-line treatment of patients with recurrent/metastatic HPV16-positive head and neck cancer: Updated results.Org: Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham Heersink School of Medicine, University of Kansas Medical Center, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Cleveland Clinic Lerner College of Medicine,
Abstract
Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma.Org: Mayo Clinic, Memorial Sloan Kettering Cancer Center, Cleveland Clinic Lerner College of Medicine, The Ohio State University - Division of Hematology, Washington University School of Medicine,
Abstract
NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC).Org: Memorial Sloan Kettering Cancer Center, NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, Washington University School of Medicine in St. Louis, Washington University School of Medicine,
Abstract
Evaluation of a polygenic risk score as a predictor of early onset triple-negative breast cancer in Black women.Org: Cleveland Clinic Lerner College of Medicine, Myriad Genetics, Inc.,
Abstract
Molecular characterization of patients with localized Ewing sarcoma targeting discrete prognostic groups: A report from the Children’s Oncology Group.Org: Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston Children's Hospital, Children's Oncology Group Statistics and Data Center, University of Florida, Cleveland Clinic Lerner College of Medicine,
Abstract
Hope drives quality of life in patients with brain metastases, but the hope center remains elusive: An analysis of NRG-CC003.Org: Sharei Zedek Hospital, NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, Northwestern Medicine Cancer Center Warrenville, Northwestern Medicine Proton Center, Baptist Health South Florida,
Abstract
Adjunctive statistical standardization of quantitated adjuvant ER and PgR in CCTG MA.27.Org: Ontario Institute for Cancer Research, Toronto, ON, Canada, MASS General Hospital BHX-1, Mayo Clinic Department of Oncology, Progendis, Caris Life Sciences,
Abstract
Neuropathy trajectory informed by algorithm-based alerts from remote symptom monitoring (RSM) tool in breast cancer practice.Org: Cleveland Clinic Lerner College of Medicine, Carevive Systems Inc., Carevive Systems, Inc., Mayfield Heights, North Miami,
Abstract
Implementation of standardized electronic documentation of goals of care discussions to improve cancer care.Org: University of California, San Diego Medical Center, Moores Cancer Center at UC San Diego Health, Cleveland Clinic Lerner College of Medicine, Endocrinology and Metabolism Institute, Doris A. Howell Palliative Care Service,
Abstract
Therapy-related myeloid neoplasm risk score (TMNRS): A convenient clinical score for TMN risk assessment at presentation in adult patients (pts) with cancer.Org: Department of Hematology and Medical Oncology at Emory University School of Medicine, Atlanta, GA, Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, Roswell Park Comprehensive Cancer Center, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine,
Abstract
Association between social determinants of health and time to treatment for newly diagnosed multiple myeloma.Org: Cleveland Clinic Lerner College of Medicine, Cleveland Clinic Taussig Cancer Institute, Case Western Reserve University School of Medicine,
Abstract
Diagnostic test use and time to cancer diagnosis in Medicare recipients.Org: GRAIL, LLC, a subsidiary of Illumina, Inc., Medicus Economics, LLC, Cleveland Clinic Lerner College of Medicine,
Abstract
Barriers to accrual and enrollment in brain tumor trials.Org: Dana-Farber Cancer Institute, Massachusetts General Hospital, University of California Irvine, The University of Texas MD Anderson Cancer Center, The University of Texas Health Science Center School of Nursing,
Abstract
Targeting glioma stem cells with thyroid hormone suppression: Phase 1/2 trial of methimazole in patients with progressive grade 4 gliomas.Org: Cleveland Clinic Lerner College of Medicine,
Abstract
A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL).Org: Miami Cancer Institute, Baptist Health South Florida, Cleveland Clinic Lerner College of Medicine, Department of Internal Medicine, William Beaumont University Hospital, The University of North Carolina at Chapel Hill,
Abstract
Impact of hormone receptor status and tumor subtypes on clinical behavior and outcomes of breast cancer in young BRCA carriers.Org: Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genoa, Genoa, Italy, Academic Trials Promoting Team, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Brussels, Belgium, U.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Genova, Italy, Department of Medical Oncology, Universite Paris Cité, Institut Curie, Paris, France, Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea,
Abstract
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.Org: Division of Hematology, Mayo Clinic, Rochester, MN, Stanford University Medical Center, Palo Alto, CA, University of Kansas Medical Center, Kansas City, KS, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
Differential genomic profiling of the progesterone receptor (PR) negative and estrogen receptor (ER) low metastatic breast cancer subtypes through circulating tumor DNA: A TNBC-like disease subtype?Org: Department of Medicine (DMED), University of Udine, Aviano, Italy, Washington University in St. Louis, St. Louis, MO, Universita degli Studi di Udine, Udine, Italy, Weill Cornell Medicine, New York, NY, Massachusetts General Hospital Cancer Center, Boston, MA,
Abstract
SurvivorCHIP: Evaluation of clonal hematopoiesis in women treated for breast cancer.Org: Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Case Western Reserve University School of Medicine,
Abstract
Identification of patients with DCIS with low-risk clinicopathology who benefit from radiation therapy with and without endocrine therapy after breast-conserving surgery assessed with the 7-gene biosignature.Org: Nashville Breast Center, Cleveland Clinc, Michigan Healthcare Professionals, University of Colorado Denver, Washington University School of Medicine,
Abstract
Phase I study of BTK inhibitor ibrutinib with temozolomide and radiation in newly-diagnosed glioblastoma (EQUILIBRIUM): Final trial report.Org: Miami Cancer Institute - Baptist Health South Florida, Baptist Health South Florida, Cleveland Clinic Taussig Cancer Instititute, Cleveland Clinic Foundation, Cleveland Clinic Brunswick Urgent Care,
Abstract
Neutrophil-to-lymphocyte ratio as a predictor of immune checkpoint inhibitor therapy response in advanced bladder cancer.Org: Cleveland Clinic Lerner College of Medicine, Cleveland Clinic Taussig Cancer Instititute, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Characterizing immune-genomic signatures associated with response to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC).Org: Cleveland Clinic Lerner College of Medicine, John D. Dingell VA Hospital, Cleveland Clinic Taussig Cancer Instititute, Cleveland Clinic Lerner Research Institute, Cleveland, OH,
Abstract
Relationship between androgen biosynthesis linked to 3βHSD1 and resistance to radiotherapy: A germline biomarker for combined androgen blockade with radiation in high-risk prostate cancer.Org: Cleveland Clinic Taussig Cancer Instititute, Cleveland Clinic Lerner College of Medicine,